FDA tentative approval means a drug application has passed the scientific review needed for approval, but the company still cannot sell that product in the United States. A patent, legal exclusivity—a period when FDA cannot approve a competitor—or another named barrier is holding back effective approval, the permission that allows marketing. Think of it as FDA saying the application is ready on the evidence it has today, while the launch still has to wait.

That is different from a rejection. It is also different from permission to put the drug on pharmacy shelves.

What FDA tentative approval means officially

Most tentative approvals involve an abbreviated new drug application, or ANDA—the application used for a generic version of a reference drug. A reference drug is the approved product the proposed generic must match on required features. Certain 505(b)(2) applications, which rely partly on studies FDA has already reviewed, can receive tentative status too.

FDA's current program dashboard gives the cleanest definition: the generic application is ready for approval, but a patent or exclusivity blocks it. The tentative letter explains the particular block, and the product cannot be marketed.

The formal rule is even plainer. Title 21, section 314.105 of the federal regulations says an ANDA can receive tentative approval when it otherwise meets the legal requirements but cannot yet be approved. It also says the status rests on the information and manufacturing conditions FDA knows at that time. New information can still change the answer.

This isn't a lesser scientific category. A 2017 FDA-authored paper on the tentative-approval program explains that applications are reviewed against the same safety, effectiveness and quality criteria used for comparable applications. The paper focuses on a special HIV program that uses tentatively approved products outside the United States; it does not turn tentative status into permission for ordinary U.S. sales.

Why tentative approval exists

The system comes from the balance Congress built into the 1984 Hatch-Waxman Act. A generic company can develop and submit its product before the brand's patents and exclusivities end. FDA can finish its scientific work during that waiting period instead of starting only after the legal protection expires.

For an ANDA, that work includes manufacturing, labeling and bioequivalence—evidence that the proposed generic delivers its active ingredient at a comparable rate and amount to the reference drug. An FDA study of 2,484 ANDA submissions from 2001 through 2008 found at least one bioequivalence deficiency in most applications (Liu et al., AAPS Journal 2012). In other words, tentative approval is not a rubber stamp. The application has already survived a detailed technical review.

What happens after tentative approval

Nothing switches automatically on the day a patent expires. The applicant still needs an approval letter. FDA may need updated labeling, manufacturing information or other material before making the approval effective. The federal statute's definition says a tentatively approved drug is not an approved drug until the agency completes any necessary additional review and issues that later approval.

The applicant also has to keep watching the reference product. If its label, manufacturing record or market status changes, the generic application may need an update. That is why “tentative” describes the application's place in time, not a permanent grade attached to the molecule.

Then there is the 180-day exclusivity wrinkle. A first applicant that files a substantially complete ANDA with a Paragraph IV certification—a formal statement that a listed patent is invalid or would not be infringed by the proposed generic—may qualify for 180 days during which later applicants cannot receive approval. More than one first applicant can share that period. FDA's current patent-certification page explains that a later applicant can be scientifically ready yet remain tentatively approved while the first applicant is eligible for that exclusivity or is using it.

So two clocks may matter: the patent or exclusivity protecting the reference drug, and the first generic applicant's 180-day period. The tentative letter and FDA's database record identify which application is waiting; they do not promise a public launch date.

How the term appeared in peptide medicine in 2026

Semaglutide gave this dry regulatory phrase a very public example. Apotex announced on April 10, 2026 that its ANDA for a proposed generic Ozempic injection had received tentative approval. The broader patent and availability story belongs in our generic semaglutide guide; the narrow point here is that the announcement did not create a U.S. product that pharmacies could sell.

As of September 9, 2026, the day this article was written, Apotex's August 12 update still described the U.S. semaglutide application as tentatively approved and said it expected a launch only after final approval following patent expiration in 2032. That is the wait built into the term, shown in a familiar medicine.

Compounding is a separate route. Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A compounded preparation is not a generic, and it does not inherit tentative status from an ANDA filed by another company.

Tirzepatide is a different active ingredient, not another version of semaglutide. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

What tentative approval does not mean

Common reading What the term actually tells you
“It is available now” The opposite: the named product cannot be marketed in the United States yet.
“FDA is still deciding whether the application meets the scientific bar” The application otherwise meets the approval requirements, although FDA can review new information before making approval effective.
“The whole ingredient is tentatively approved” The status belongs to one application for one finished product.
“A compounded version is the waiting generic” Compounding and ANDA review are separate legal routes.
“Patent expiry guarantees a launch that day” FDA must still issue the approval letter, and other exclusivity or application updates may matter.

The safest way to read a tentative-approval announcement is to ask three questions: Which exact application received the letter? What legal barrier does the letter name? Has FDA issued the later approval letter that permits marketing? If the third answer is no, the product is not a marketed U.S. generic.

An ANDA is the generic-drug application. A 505(b)(2) application is a new-drug application that can rely partly on findings or studies the applicant does not own. A reference listed drug is the approved product an ANDA points back to. None of those terms describes pharmacy compounding.

For the separate ingredient rules that apply to traditional compounding pharmacies, see the 503A bulks list explained. For the clinical-trial and new-drug route, see the not-yet-approved pathway. Those pages describe different decisions, made for different purposes.

At Promise, a licensed provider reviews every request, and not everyone qualifies. Tentative status on someone else's application neither replaces that medical review nor decides whether an individual prescription is appropriate.